Oregon PDAB

Comment addressing Oregon PDAB's March 2026 meeting on orphan drug interpretation and support for rebate pass-through affordability solutions.

Comment addressing Oregon PDAB's January 2026 meeting on orphan drug review exclusions and HIV medication affordability considerations.

Comment on Oregon PDAB's December 2025 meeting addressing ongoing affordability review developments and UPL policy implementation concerns.

Comment on Oregon PDAB's November 2025 meeting addressing drug review outcomes, affordability determination processes, and ongoing advocacy for patient protections.

Comment on Oregon PDAB's affordability determinations and policy recommendations, providing feedback on proposed actions and their potential impact on patient access and safety-net providers.

Comment on Oregon PDAB's ongoing review developments, addressing progress on affordability determinations and continued advocacy for patient access protections.

Comment on Oregon PDAB's individual drug reviews, addressing review methodology and advocating for considerations of safety-net program impacts in affordability determinations.

Comment on Oregon PDAB's affordability review process, addressing analytical methodology, stakeholder engagement, and recommendations for patient-protective review criteria.

Comment on Oregon PDAB's subset drug list selection and board goals, addressing prioritization methodology and alignment with patient-centered affordability objectives.

Comment on Oregon PDAB's drug list for affordability review, addressing selection criteria, patient impact considerations, and protection of medications critical to safety-net programs.

Comment urging Oregon PDAB to exclude antiretrovirals from affordability review due to federal program dependencies and potential harm to HIV treatment access through Ryan White and 340B programs.

Comment addressing Oregon PDAB's February 2025 meeting agenda, raising concerns about affordability review processes and UPL development methodology.

Comment on Oregon PDAB's conflict of interest policies, addressing transparency requirements and board member accountability in affordability review processes.

Comment opposing listing HIV antiretrovirals for Oregon PDAB affordability review, citing federal protections for these medications and the dependence of Ryan White programs on 340B rebates for treatment access.

Comment opposing Oregon's proposed UPL implementation, citing weak cost-benefit analysis, PBM manipulation of drug pricing, and risks to 340B provider revenues and patient access to antiretroviral therapies.

Comment supporting Oregon PDAB's policy recommendations while opposing UPL cost-benefit analysis findings, recommending PBM reform and additional transparency measures as more effective alternatives.